About PT-141 (Bremelanotide)
PT-141 (Bremelanotide) is a cyclic heptapeptide derived from Melanotan 2 that selectively targets the MC4R receptor to act on central arousal pathways. FDA-approved as Vyleesi in 2019 for HSDD.
Reported benefits
- MC4R-selective - central nervous system arousal pathway
- Onset within 30–60 minutes of subcutaneous dose
- FDA-approved active compound (Vyleesi)
Research citations
- Clayton et al. 2016 - Obstetrics & Gynecology
- Diamond et al. 2006 - Journal of Sexual Medicine
How PT-141 (Bremelanotide) fits the category
PT-141 (Bremelanotide) sits inside the Best Peptides for Aesthetic category. For the full ranking and head-to-head comparisons, read Best Peptides for Aesthetic.
